Latest advances and outcomes from the treatment of acute leukemia today
Leukemia is a blood cancer that can be identified by the rapid growth of defective
blood cells. The marrow of our bone produces most of the blood in our body which is
the site of this abnormal growth. Typically, leukemia cells are immature white blood
cells. Leukemic cells alter the normal blood cell formation process, leading to various
signs and symptoms such as bleeding, infection, and tiredness.
There are two kinds of leukemia: acute leukemia and chronic leukemia. Further, the
acute type was classified into acute myeloid leukaemia (AML) and acute
lymphoblastic leukaemia (ALL). Myeloblasts, or defective white blood cells, are the
cause of acute myeloid leukaemia (AML). Acute myelogenous, granulocytic,
nonlymphocytic, or myeloblastic leukaemia are other terms for this kind of cancer.
However, the overproduction of lymphocytes is caused by acute lymphoblastic
leukaemia (ALL).
Stem cell transplantation, radiation therapy, and chemotherapy have been the
cornerstones of leukaemia treatment. Targeted therapy has also been included in the
standard of care for certain kinds of leukaemia within the past 20 years. These
medications target the proteins that regulate the growth, division, and metastasis of
cancer cells. Different treatment combinations are needed for different forms of
leukaemia.
For Acute lymphocytic leukemia (ALL), Immunotherapies are being used where
many elderly people are unable to handle the severe side effects of the intense
chemotherapy therapies required to treat ALL. Compared to chemotherapy, targeted
therapies might have fewer adverse effects.
Immunotherapies are treatments that enhance the body's ability to fight cancer
through the immune system. Currently, four immunotherapies are FDA approved for
the treatment of ALL: blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and
midostaurin. In ALL, the following immunotherapy techniques are being tested or
employed are CAR T-cell therapy and bispecific T-cell engagers (BiTEs). A sort of
cancer treatment called CAR T-cell therapy involves genetically modifying the
patient & own immune cells. For the treatment of some children and young adults with
ALL, one kind of CAR T cell therapy is currently approved. Dosing is based on
weight reported at the time of leukapheresis.The use of this type in elderly B-cell
ALL patients is now being investigated. Adults with B-cell precursor ALL who have
not responded to previous treatment or have returned after treatment have been
approved for another course of CAR T-cell therapy.
Bispecific T-cell engagers (BiTEs) are another immunotherapy that is being studied
for ALL. These medications bind to both cancer and immune cells, drawing the two
groups of cells closer together so that the immune cells can locate and eliminate the
cancer cells with ease. Recently, it was demonstrated that one such BiTE,
blinatumomab, can increase survival for ALL patients in remission following
chemotherapy, even in situations where the disease is completely eradicated.
Acute myeloid leukaemia (AML) tends to be aggressive and was harder to treat than
ALL. However, AML cells sometimes have gene changes that cause the tumors to
grow but can be targeted with new drugs. The management of AML involves two
phases such as remission induction therapy (first phase of treatment to kill
the leukemia cells in the blood and bone marrow ) and remission continuation therapy
(second phase of treatment to kill any remaining leukemia cells).
The treatment of AML includes chemotherapy (drugs to stop the growth of cancer
cells), radiation therapy (uses high-energy x-rays or other types of radiation to kill
cancer cells), stem cell transplant (to replace the blood-forming cells from the blood
or bone marrow of the patient) and targeted therapy (drugs or other substances to
identify and attack specific cancer cells) or combination of both. Targeted treatments
such as Enasidenib, Olutasidenib, Ivosidenib, Venetoclax, Gemtuzumab ozogamicin,
Midostaurin, Gilteritinib, Glasdegib, and Quizartinib have recently been approved to
treat AML with specific gene alterations.
In order to achieve complete remission (CR) from acute leukaemia, standard
treatment paradigms have involved high-intensity induction chemotherapy. In certain
cases, this was followed by an allogeneic hematopoietic cell transplant (allo-HCT) to
eliminate residual disease through the "graft versus leukaemia effect, which is
mediated by the immune cells of the donor. Allo-HCT is not recommended for all
patients, though, and one of the biggest problems facing the industry at the moment is
the lack of viable chemotherapy-based choices for patients who relapse after allo-
HCT or who develop chemotherapy-refractory illness.
The potential of immunotherapy in the treatment of acute myeloid leukaemia (AML)
has been established by the effectiveness of allogeneic stem cell transplantation.
Alternative T-cell-based immunotherapies have demonstrated effectiveness, but there
is a chance that they could cause on-target off-leukemia hematotoxicity. Currently,
the use of adoptive autologous or allogeneic chimeric antigen receptor (CAR) T /
natural killer cell treatment as a bridge-to-transplant approach is almost only available
in clinical studies.
Acute leukaemia used to be nearly always fatal, but now it has a 63% 5-year survival
rate in the US. The therapeutic options for acute leukaemia have increased with the
introduction of immunotherapy, however, the advancement in AML has been slower.
Novel medicines such as ADCs, CAR T cell treatments, and BiTEs continue to show
remarkable response rates and favourable toxicity profiles in various disease states
every year. Even with these developments, a large number of patients are still not
eligible for immunotherapeutic treatments, and relapses following some of the more
recent modalities are still linked to extremely poor prognoses. In the future, new
medicines with potentially unique mechanisms of action will probably be approved
together with the expansion of the indications for currently available medications.
References:
1. Leukemia. National Cancer Institute. Available at:
https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
2. Boyiadzis MM, Aksentijevich I, Arber DA, et al. The Society for Immunotherapy
of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of
acute leukemia. Journal for ImmunoTherapy of Cancer. 2020
3. Kantarjian, H., Kadia, T., DiNardo, C. et al. Acute myeloid leukemia: current
progress and future directions. Blood Cancer J. 2021
4. Subklewe M, Bücklein V, Sallman D, Daver N. Novel immunotherapies in the
treatment of AML: is there hope? Hematology Am Soc Hematol Educ Program. 2023
Dec 8;2023
Share:
More Posts
Appendix Cancer Treatment in Bangalore
Appendix cancer is a rare type of cancer that starts in the appendix, a small pouch attached to the large intestine. While it is uncommon, it can be serious if not detected and treated early. Many patients discover appendix cancer accidentally during surgeries for other conditions, such as appendicitis. At Healius Cancer & Hematology Clinics, Bangalore, under the expertise of Dr. Mangesh Kamath, patients receive accurate diagnosis, advanced treatments, and compassionate care for appendix cancer. This blog will help you understand appendix cancer, its types, symptoms, risk factors, diagnostic procedures, and treatment options available in Bangalore. What is Appendix Cancer? Appendix cancer occurs when abnormal cells grow uncontrollably in the appendix. Depending on the type, it may be slow-growing or aggressive, potentially spreading to other organs. Unlike other gastrointestinal cancers, appendix cancer often has no obvious symptoms in its early stages. Types of Appendix Cancer Symptoms of Appendix Cancer Appendix cancer symptoms often mimic other abdominal problems, making early detection challenging: In many cases, the cancer is discovered unexpectedly during surgery for suspected appendicitis. Causes and Risk Factors While the exact cause is unknown, certain factors may increase the risk: Diagnosis of Appendix Cancer At Healius Cancer & Hematology Clinics, diagnosis involves: Appendix Cancer Treatment in Bangalore Treatment depends on the type, size, and stage of the cancer: 1. Surgery 2. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) 3. Systemic Chemotherapy 4. Targeted Therapy & Immunotherapy Why Choose Healius Cancer & Hematology Clinics, Bangalore? Life After Appendix Cancer Treatment Recovery depends on the stage at which cancer is diagnosed and the type of treatment used. Many patients lead healthy lives post-treatment with proper follow-up and lifestyle adjustments: Conclusion Appendix cancer is rare, but early diagnosis and advanced treatment can significantly improve survival rates. At Healius Cancer & Hematology Clinics, Bangalore, Dr. Mangesh Kamath and his team ensure that patients receive the latest and most effective treatments with a compassionate approach. If you or your loved one is diagnosed with appendix cancer, don’t delay consultation. 📞 Call 9900613143 today to book an appointment with Dr. Mangesh Kamath and begin your journey towards recovery.
How Breastfeeding Protects Women from Breast Cancer
How Breastfeeding Protects Women from Breast Cancer Breast cancer is one of the most common cancers affecting women worldwide. While genetics, age, and lifestyle factors play a significant role in its development, research shows that breastfeeding offers a natural and effective way to reduce the risk. Breastfeeding not only benefits the baby by providing essential nutrition and immunity but also protects the mother’s health in multiple ways. In this article, we’ll explore how breastfeeding acts as a protective shield against breast cancer, backed by medical research, expert opinions, and practical advice from Dr. Mangesh Kamath, Senior Consultant in Medical Oncology, Hemato-Oncology, and Bone Marrow Transplant at Healius Cancer & Hematology Clinics, Bangalore. Understanding Breast Cancer Breast cancer develops when abnormal cells in the breast grow uncontrollably, forming a tumor. These cells can invade surrounding tissues or spread (metastasize) to other parts of the body. Some common risk factors include: While some of these risk factors cannot be changed, lifestyle choices—including breastfeeding—can significantly reduce the likelihood of developing the disease. How Breastfeeding Reduces Breast Cancer Risk 1. Hormonal Changes During Breastfeeding When a woman breastfeeds, her body produces less estrogen and progesterone—hormones that can promote the growth of certain breast cancer cells. Reduced exposure to these hormones lowers the risk of cancer development. 2. Shedding of Breast Tissue During lactation, the breast undergoes changes to produce milk. After breastfeeding ends, the body naturally sheds breast tissue. This process can help eliminate cells with potential DNA damage, reducing the likelihood of them turning cancerous. 3. Delay in Menstrual Cycles Exclusive breastfeeding can delay the return of regular menstrual cycles (lactational amenorrhea). This reduces the total number of menstrual cycles a woman experiences in her lifetime, thus lowering lifetime hormone exposure. 4. Enhanced Differentiation of Breast Cells Breast cells mature and change during pregnancy and breastfeeding, making them more resistant to mutations that can lead to cancer. Scientific Evidence Supporting the Benefits Numerous studies have shown a link between breastfeeding and lower breast cancer risk: How Long Should You Breastfeed for Maximum Benefit? While any duration of breastfeeding provides health benefits, research suggests: Additional Health Benefits of Breastfeeding Breastfeeding’s benefits go beyond breast cancer prevention: Overcoming Common Breastfeeding Challenges Many women face difficulties in breastfeeding, such as: Tips to Overcome Challenges: When to Consult a Doctor While breastfeeding offers protection, it’s not a guarantee against breast cancer. Be alert for warning signs: If you notice any of these, seek prompt medical attention. Expert Advice from Dr. Mangesh Kamath According to Dr. Mangesh Kamath, “Breastfeeding is one of the simplest and most natural steps women can take to lower their breast cancer risk. Even partial breastfeeding can have a positive effect. However, regular breast screenings and a healthy lifestyle remain essential for overall protection.” Lifestyle Tips to Complement Breastfeeding’s Protective Effect Key Takeaways Conclusion Breastfeeding is more than a way to nourish your baby—it’s a powerful, natural strategy for protecting your long-term health. Backed by scientific evidence, it plays a significant role in reducing breast cancer risk. If you have questions about breast health, cancer prevention, or need guidance on breastfeeding challenges, visit Healius Cancer & Hematology Clinics in Bangalore and consult Dr. Mangesh Kamath for personalized care.
Lung Cancer Treatment in Bangalore | Dr. Mangesh Kamath – Healius Clinics
Lung cancer is one of the most common cancers worldwide, affecting both men and women. Early detection and effective treatment can significantly improve survival rates. At Healius Cancer & Hematology Clinics, we provide advanced lung cancer care under the expertise of Dr. Mangesh Kamath, one of Bangalore’s leading cancer specialists. What is Lung Cancer?Lung cancer begins in the lungs and can spread to other parts of the body if not treated promptly. It is typically classified into two main types: Causes and Risk Factors Symptoms of Lung Cancer Diagnosis at Healius ClinicsWe use advanced diagnostic tools such as CT scans, PET scans, bronchoscopy, and biopsy to ensure accurate detection. Treatment Options At Healius Cancer & Hematology Clinics, we provide a comprehensive approach including: Why Choose Dr. Mangesh Kamath? Contact Details📞 Call: 9900613143📍 Healius Cancer & Hematology Clinics, Bangalore ConclusionIf you or a loved one is facing lung cancer, early consultation can make all the difference. Get expert, compassionate care from Dr. Mangesh Kamath at Healius Cancer & Hematology Clinics.
Chronic Lymphocytic Leukaemia (CLL): The Slow but Manageable Blood Cancer
Chronic Lymphocytic Leukaemia (CLL): The Slow but Manageable Blood Cancer 🩸 What is CLL? Chronic Lymphocytic Leukaemia (CLL) is a type of blood and bone marrow cancer where the body makes too many abnormal white blood cells called lymphocytes. These cells look normal but do not work properly to fight infections. Over time, they build up in the blood, bone marrow, and lymph nodes, pushing out the healthy cells. Unlike aggressive leukaemia’s like AML or ALL, CLL is slow-growing. Many people live with CLL for years before needing treatment. In fact, some people may never need active therapy and are only monitored. 🌍 How Common is CLL? ⚠️ Risk Factors and Causes The exact cause of CLL is not known. But certain risk factors make it more likely: 👉 CLL is not contagious and is not caused by lifestyle or diet. 🔍 Common Symptoms of CLL Many patients are diagnosed during a routine blood test without any symptoms. When present, symptoms may include: 🧪 How is CLL Diagnosed? 🎯 Risk Stratification in CLL CLL does not behave the same way in every patient. Some people live for decades without treatment, while others need immediate therapy. Risk stratification helps doctors decide the best approach. 🔹 Risk Stratification Systems in CLL: 👉 These risk groups guide whether a patient should be on watch & wait, given tablets, or considered for advanced therapies. 💊 Treatment Options for CLL 1. Watchful Waiting (Active Surveillance) 2. Targeted Therapy 3. Chemo-Immunotherapy 4. Monoclonal Antibodies 5. Stem Cell Transplant 🚀 Recent Advances in CLL Treatment 📊 CLL vs Other Leukaemias – A Simple Comparison Feature CLL CML ALL AML Progression Slow (chronic) Slow (chronic) Fast (acute) Fast (acute) Typical Age >60 yrs 40–60 yrs Children & young adults Mostly adults, esp. >60 yrs Cells Involved Lymphocytes Myeloid cells Immature lymphoblasts Immature myeloid cells Symptoms Often none early; enlarged nodes, fatigue Fatigue, splenomegaly, high WBC Fever, bleeding, bone pain Fatigue, bleeding, infections Treatment Watchful waiting, targeted therapy, antibodies TKIs (Imatinib, etc.), sometimes transplant Chemotherapy, targeted therapy, immunotherapy Intensive chemo, transplant Curability Usually controlled for years; remission possible Excellent long-term control with TKIs High cure rates, esp. in children Curable with aggressive therapy but relapse risk exists 🌈 Living with CLL: A Message of Reassurance CLL is often called a “chronic” cancer, meaning it can be controlled long-term. Many patients live a normal lifespan, especially with today’s advanced therapies. For many, CLL becomes a condition that is managed like diabetes or hypertension rather than a life-ending disease. Regular follow-up, timely treatment when needed, and support from family and healthcare teams make a huge difference. ❤️ Final Thoughts From Healius Cancer and Haematology Clinics At Healius Cancer and Haematology Clinics, we understand the anxiety that comes with a diagnosis of CLL. The good news is that treatment has advanced tremendously—from chemotherapy to highly effective targeted therapies that give excellent quality of life. Under the guidance of Dr. Mangesh Kamath, our team provides: 👉 Remember: CLL is not the end. With modern science, it is a journey that can be lived with hope, strength, and dignity.
